Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.63 |
| ▸ | SCTR | P47872 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663731 | 0.97 | GLP1R (0.66) | GLP1RSCTR | |
| SCHEMBL30978208 | 0.96 | GLP1R (0.65) | GLP1RSCTR | |
| SCHEMBL30278876 | 0.95 | GLP1R (0.60) | GLP1RSCTR | |
| SCHEMBL31058454 | 0.95 | GLP1R (0.71) | GLP1RSCTR | |
| SCHEMBL31058452 | 0.95 | GLP1R (0.71) | GLP1RSCTR | |
| SCHEMBL30320200 | 0.94 | GLP1R (0.56) | GLP1RSCTR | |
| SCHEMBL30207768 | 0.94 | GLP1R (0.56) | GLP1RSCTR | |
| SCHEMBL30320225 | 0.94 | GLP1R (0.56) | GLP1RSCTR | |
| SCHEMBL30320221 | 0.94 | GLP1R (0.56) | GLP1RSCTR | |
| SCHEMBL29913342 | 0.94 | GLP1R (0.56) | GLP1RSCTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073582-B | Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications | 深圳市图微安创科技开发有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-112791178-B | GLP-1R/GCGR dual agonist polypeptide derivatives for preventing or treating renal fibrosis | 深圳市图微安创科技开发有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-114585640-B | GLP-1R/GCGR double-target agonist polypeptide derivative for treating liver fibrosis related to viral hepatitis | 深圳市图微安创科技开发有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-114945589-B | Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications | 深圳市图微安创科技开发有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-112898405-B | Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications | 深圳市图微安创科技开发有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-106046145-B | GLP-1R/GCGR dual-target agonist polypeptides for treating fatty liver disease, hyperlipidemia and arteriosclerosis | 深圳市图微安创科技开发有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-115181175-A | GLP-1R/GCGR dual-target agonist polypeptides for treating fatty liver disease, hyperlipidemia and arteriosclerosis | 深圳市图微安创科技开发有限公司 | 2022-10-14 | — | — | CN | claimed |
| EP-4724472-A2 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | disclosed |
| CN-115073582-B | Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications | 深圳市图微安创科技开发有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024252367-A2 | NOVEL GLP-1/GIP DUAL AND GLP-1/GCG DUAL RECEPTOR AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-12-12 | — | — | WO | disclosed |
| CN-112791178-B | GLP-1R/GCGR dual agonist polypeptide derivatives for preventing or treating renal fibrosis | 深圳市图微安创科技开发有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-114585640-B | GLP-1R/GCGR double-target agonist polypeptide derivative for treating liver fibrosis related to viral hepatitis | 深圳市图微安创科技开发有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240174728-A1 | A USE OF A POLYPEPTIDE COMPOUND IN THE PREPARATION OF DRUGS FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASES AND RELATED INTESTINAL FIBROSIS | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2024-05-30 | — | — | US | disclosed |
| CN-114945589-A | Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications | 深圳市图微安创科技开发有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | SHENZHEN TURIER BIOTECH CO., LTD. | 2022-08-23 | — | — | US | disclosed |
| CN-114920818-A | Treatment of biliary cirrhosis based on oxyntomodulin analog GLP-1R/GCGR dual-target agonist polypeptide | 深圳市图微安创科技开发有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022156189-A1 | USE OF POLYPEPTIDE COMPOUND IN PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND INTESTINAL FIBROSIS RELATED THERETO | 深圳市图微安创科技开发有限公司 | 2022-07-28 | — | — | WO | disclosed |
| CN-111278853-B | Treatment of biliary cirrhosis based on oxyntomodulin analog GLP-1R/GCGR dual-target agonist polypeptide | 深圳市图微安创科技开发有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114585640-A | GLP-1R/GCGR double-target agonist polypeptide derivative for treating viral hepatitis-related liver fibrosis | 深圳市图微安创科技开发有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022061924-A1 | GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE DERIVATIVES FOR TREATMENT OF VIRAL HEPATITIS-RELATED HEPATIC FIBROSIS | 深圳市图微安创科技开发有限公司 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | GCGR, GLP1R, GIPR | GLP1R 2/4885SCTR 11/4885 |
| US-20240174728-A1 | A USE OF A POLYPEPTIDE COMPOUND IN THE PREPARATION OF DRUGS FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASES AND RELATED INTESTINAL FIBROSIS | VIP, FN1, COL14A1 | GLP1R 114/4885SCTR 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.